___

• 1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129 (3):606-16. 2. Martinez-Altarriba M, Ramos-Campoy O, Luna-Calcaño M, Arrieta-Antón E. A review of multiple sclerosis. Diagnosis and treatment Semergen 2015; 41(5):261-5. 3. Wiles C M, Newcombe R G, Fuller K J, Shaw S, Furnival-Doran J, Pickersgill T P, Morgan A. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis J Neurol Neurosurg Psychiatry 2001;70:174–79 4. World Health Organization (WHO). “Effective Public Education” in promoting rational drug use. WHO Programme on Essential Drugs and International Network for the Rational Use of Drugs, Nairobi, 1987. 5. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM: Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61(11): 1524–1527. 6. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999; 11;53(4):883-5. 7. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71(2): 129–35. 8. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008;15(9): 916–21. 9. Convraveux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126(4): 770–82. 10. Taylor KL, Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, et al. Lifestyle factors, demographics and medications associated with depression risk in an internationalsample of people with multiple sclerosis. BMC Psychiatry 2014; 3;14(1):327. 11. Mrabet S, Ben Ali N, Kchaou M, Belal S. Depression in multiple sclerosis. Rev Neurol 2014;170(11):700-2. 12. Moghaddasi M, Mamarabadi M, Mirzadeh S, Freydoonnejad A, Razjouyan H. Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke Neurological Research 2010; 32(9): 953–956. 13. Reyold E.H. Multiple sclerosis and vitamin b12 metabolism. Journal of Neurology Neurosurgery, and Psychiatry 1992; 55(5); 339–340. 14. ZychTwardowska E, Wajgt A. Blood levels of selected hormones in patients with multiple sclerosis. Med Sci Monit. 2001;7(5):1005-12. 15. Long Y, Zheng Y, Chen M, Zhang B, Gao C, Shan F, et al. Serum thyroid-stimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases. PLoS One 2014; 9(8):100672. 16. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011; 4(8):127. 17. Da Costa R, Szyper-Kravitz M, Szekanecz Z, Csépány T, Dankó K, Shapira Y, et al. Ferritin and Prolactin Levels in Multiple Sclerosis. Isr Med Assoc J 2011; 13(2):91-5. 18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disabilitystatus scale (EDSS). Neurology 1983; 33 (11):1444-52.